FDA approves Ionis’ hereditary angioedema drug
Written by
BioPharma Dive
Published
0
comments
0
min
Dawnzera is the third medicine cleared by U.S. regulators this year for the rare genetic condition. Ionis set its list price at $57,462 per dose.